Characterization of a thrombin cleavage site mutation (Arg 1689 to Cys) in the factor VIII gene of two unrelated patients with cross-reacting material-positive hemophilia A.
The molecular defect responsible for moderate and severe hemophilia A has been identified for two unrelated patients with the CRM-positive form of this disorder (factor VIII activity of 0.02 and 0.05 U/mL with factor VIII antigen of 0.87 and 2.20 U/mL). In both cases, the immunopurified dysfunctional factor VIII protein is abnormal, in that the 80 Kd light chain is not cleaved by thrombin at arginine-1689. The basis for this failure was identified by polymerase chain reaction amplification of exon 14 of the variant factor VIII genes and direct sequencing of the amplified products. In both cases, a single base substitution (C to T) was identified that produces an arginine to cysteine substitution at amino acid residue 1689. These data identify the molecular defects of the two identical factor VIII variant proteins. The dysfunctional factor VIII has been designated "Factor VIII-East Hartford," the residence of the patient in whom the defect was first identified.
Arai
M
M
Jerome H. Holland Laboratory for the Biomedical Sciences, American Red Cross Blood Services, Rockville, MD.
Higuchi
M
M
Antonarakis
S E
SE
Kazazian
H H
HH
Phillips
J A
JA
Janco
R L
RL
Hoyer
L W
LW
D001120:Arginine; D001483:Base Sequence; D003429:Cross Reactions; D005169:Factor VIII / Q000235:genetics* / Q000276:immunology; D006467:Hemophilia A / Q000235:genetics*; D006801:Humans; D007163:Immunosorbent Techniques; D008969:Molecular Sequence Data; D009154:Mutation; D016133:Polymerase Chain Reaction; D013917:Thrombin / Q000378:metabolism
D005169:Factor VIII; D001120:Arginine; D013917:Thrombin